Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07568236
PHASE2

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

Sponsor: Chinese University of Hong Kong

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.

Official title: A Phase II Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) for Prostate Cancer (Fez-Cap)

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

54

Start Date

2026-07-01

Completion Date

2028-03-31

Last Updated

2026-05-05

Healthy Volunteers

No

Interventions

DRUG

Fezolinetant

Fezolinetant 45 mg orally once daily for 12 weeks.

DRUG

Placebo

Placebo orally once daily for 12 weeks.

Locations (1)

Prince of Wales Hospital

Shatin, Hong Kong